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OLICERIDINE’S ROLE IN PAIN 
MANAGEMENT: A QUALITATIVE 
LITERATURE REVIEW 
Melissa Reilly, PharmD, BCGP, 
Hallie Austin, PharmD candidate 2023
INTRODUCTION
• Oliceridine (Olinvyk) is a novel opioid for moderate to 
severe pain management for use in the clinical setting. 
• As an opioid agonist, it is relatively selective for the mu-
opioid receptor, and it serves as the first mu-opioid 
receptor G protein pathway selective modulator. 
• With its novel mechanism of action, oliceridine was 
designed to improve μ-opioid receptor pharmacology and 
decrease opioid related adverse effects.
OBJECTIVES
This literature review 
sought to identify the 
role oliceridine may have 




• Qualitative literature review 
• 2014-2019
• Search terms 
• PubMed - “oliceridine” 
METHODS
INCLUSION CRITERIA EXCLUSION CRITERIA
Randomized control trial Review articles




R E S U LT S
41studies populated from “oliceridine” 
search





















1.5 mg, 0.1 mg
1.5 mg, 0.35 mg
1.5 mg, 0.5 mg
M:
4 mg, 1 mg
Placebo Respiratory Safety Burden: 
Oliceridine vs placebo: P > 0.05 
Morphine vs. placebo: P < 0.05 
GI adverse effects:




O vs. placebo (efficacy)
O 0.1 mg: P = 0.029 
O 0.35 mg: P < 0.0001 
O 0.5 mg: P = 0.0004 
M (1 mg) vs. placebo





Age 18 - 89
O:
0.9 to 223.5 mg
placebo The incidence of AEs leading to 
early discontinuation and serious 
AEs were 2% and 3%, respectively.
rapid reduction in NRS pain score by 2.2 ± 2.3 at 
30 mins from a score of 6.3 ± 2.1 (at baseline) 









1.5 mg, 0.1 mg
1.5 mg, 0.35 mg
1.5 mg, 0.5 mg
M:
4 mg, 1 mg




GI adverse effects: 
O vs M
P<0.05
O vs. placebo: all P<0.0001 
% treatment responders:
Placebo: 15.2%
O 0.1 mg: 50%
O 0.35 mg: 62%
O 0.5 mg: 65.8%










(loading dose, demand dose)
O:
A: 1.5 mg, 0.1 mg (n=39)
B: 1.5 mg, 0.35 mg (n=39)
M:
4 mg, 1 mg (n=83)
Placebo O 0.1 mg vs placebo: P=0.0001 
O 0.35 mg vs placebo: P=0.0005
M vs placebo: P<0.0001








O: 0.5, 1, 2, & 3 mg
M: 4 mg
Placebo O v Placebo
O 0.5 mg; P = 0.1832
O 1 mg; P = 0.2311
O 2 mg; P = 0.0024
O 3mg; P < 0.0001






1.5, 3, 4.5 mg
Placebo O vs placebo:
O 3 & 4.5mg (P < .02) 1.5-mg (P < .007) 
O v M:
3 mg (P < .02;)





-Most studies reviewed did not have 
significant P values, providing evidence for 
less efficacy against morphine.6
-Only one study conducted by Soergel and 
colleagues had significant findings for 
oliceridine’s efficacy compared to 
morphine’s efficacy.1,2,3,4,5
-Although the 3 and 4.5 mg oliceridine
doses were both proven efficacious against 
morphine, the higher dose was more 
significant. (O 3 mg: P < .02; O 4.5 mg: P < 
.005)6
Oliceridine vs. placebo:
-Most studies reviewed had significant 
P values, providing evidence for efficacy 
against placebo.1,2,3,4,6 
-Measurements looked at for efficacy
include responder rates1,3,  pain 
scores2,4, NRS TWA0-48, changes5, and 
CPT hand removal latencies.6
-Only one study conducted by Viscusi
and colleagues showed no significance 
in oliceridine’s (low dose) efficacy 




• Most studies showed a tolerable safety profile 
in regard to adverse effects. 
• A study conducted by N Singla, HS Minkowitz, 
and colleagues demonstrated that oliceridine
has an acceptable safety/tolerability profile and 
potentially wider therapeutic window than 
morphine. 
• ER Viscusi and colleagues also demonstrated 
favorable safety and tolerability regarding GI 
and respiratory effects compared to morphine.3
• the supplemental oxygen requirements for 
the oliceridine 0.1, 0.35, and 0.5 mg groups 
were significantly less than the morphine 1 
mg group (p < 0.01). 
• GI adverse effects for the oliceridine 0.1, 
0.35, and 0.5 mg groups were significantly less 
than the morphine 1 mg group (p < 0.05).





• None of the studies reviewed compared 
oliceridine to non-opioids.
• The only other opioid that oliceridine has been 
compared to from our pool of studies is 
morphine. 
• Dosing
• Equianalgesic dosing has not yet been defined so 
comparative doses of oliceridine and morphine 
was inconsistent.
• In a study conducted by SD Bergese and colleagues, 
no control group or comparator group was used.
• Most studies looked at efficacy of oliceridine
compared to placebo only rather than also looking 
at oliceridine vs morphine efficacy.
CONCLUSION
• Based on currently available literature, oliceridine’s use in clinical practice is limited to 
patient populations undergoing procedures such as abdominoplasties & 
bunioectomies or that have painful non-surgical medical conditions. 
• In addition, most studies conducted have looked only at oliceridine efficacy and safety 
regarding side effects, but none have looked at reducing abuse potential in humans. 
• One study by C Zamarripa, SR Edwards, and colleagues demonstrates that TRV130 
produces reinforcing and antinociceptive effects that are quantitatively similar to
oxycodone, and that a biased-signaling profile does not necessarily reduce abuse 
potential. 7
• Even though this study was conducted in rats, it could be argued that this effect could 
be similar in humans.
• Do we really need a new IV opioid during an opioid epidemic when we should focus 




Future studies should evaluate 
oliceridine compared to other 
available intravenous opioids and 
non-opioids as far as efficacy, safety, 
dependency, and costs.
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